CAS: 500287-72-9; (E)-4-((4-((4-(2-Cyanovinyl)-2,6-Dimethylphenyl)Amino)Pyrimidin-2-yl)Amino)Benzonitrile

该化合物是一种主要用于治疗HIV-1感染的抗逆转录病毒药物,属于非核反转转录酶抑制剂(NNRTIs)和功能类,抑制反转转录酶酶,这对病毒复制至关重要;Rilpivirine的特点是其相对长的半衰期,允许一次剂量,这可以加强病人对治疗疗程的耐用性;该化合物通常以平板形式施用,并经常与其他抗逆转录病毒剂相结合,以提高疗效和降低抗药性风险;Rilpivirine与其他抗逆转录病毒药物相比,具有有利的副作用,其某些不利影响的发生率较低,例如胃肠紊乱和新陈代谢并发症;然而,该物质在高病毒负荷的病人或服用某些可能发生反作用的药物的病人中是受感染的.总的来说,Rilpirine是艾滋病毒管理的一个重要选择,有助于改善病人的治疗结果.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号873-74-5 对氨基苯腈 | CAS号244768-32-9 4-[(4-氯-2-嘧啶基)氨基]苯甲腈 | CAS号24596-19-8 4-溴-2,6-二甲基苯胺 | CAS号3095-47-4 4-氨基-3,5-二甲基苯甲酸乙酯] | CAS号823786-21-6 4-(4-(4-(羟基甲基)-... | CAS号708254-90-4 4-(2-(4-氰基苯基氨基)... | CAS号87-62-7 2,6-二甲基苯胺 | CAS号4102-53-8 4-碘-2,6-二甲基苯胺 | CAS号1228671-28-0 4-(4-methoxypyr... | CAS号700361-47-3 利匹韦林盐酸盐

合成工艺路线路线简述

    4-{[4-({4-[(E)-2-氰基乙烯基]-2,6-二甲基苯基}氨基)-2-嘧啶基]氨基}苯甲腈盐酸盐(1:1)置于potassium Carbonate体系中,用 水 作为反应溶剂,化学反应 3.0H,以18.6 G的收率获得产物利匹韦林
    参考文献: Improved Process For Preparation Of Rilpivirine And Pharmaceutically Acceptable Salts Thereof[fr] Procédé Amélioré Pour La Préparation De Rilpivirine Et De Sels Pharmaceutiquement Acceptables De Celle-Ci
    标题: Improved Process For Preparation Of Rilpivirine And Pharmaceutically Acceptable Salts Thereof[fr] Procédé Amélioré Pour La Préparation De Rilpivirine Et De Sels Pharmaceutiquement Acceptables De Celle-Ci
    摘要:本发明公开了一种改进的利托那韦盐酸盐制备工艺.该工艺包括a) 在相转移催化剂的存在下,反应3-(4-氨基-3,5-二甲基苯基)-丙烯腈盐酸盐和4-[(4-氯嘧啶-2-基)氨基]苯腈,然后与酸盐化;b) 将利托那韦酸加盐转化为利托那韦盐酸盐.

    海关参考信息

    专利信息


    专利号:US-2022233673-A1
    优先权日:2019-06-04
    标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
    发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
    权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
    摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

    专利号:US-2025179033-A1
    优先权日:2021-12-30
    标 题 :New antiviral triazole derivatives, their synthesis and their use for treatment of mammalian viral infections
    发明人:MAKAROV VADIM; RIABOVA OLGA; LANE THOMAS R; EKINS SEAN
    权利人:COLLABORATIONS PHARMACEUTICALS INC; FEDERAL RES CENTER FUNDAMENTALS OF BIOTECHNOLOGY RUSSIAN ACADEMY OF SCIENCE
    摘要:A family of triazole derivatives is described. Also described is the use of these triazole derivatives in treating or preventing viral infections, such as human immunodeficiency virus (HIV) infections, and the diseases caused by these infections, such as acquired immunodeficiency syndrome (AIDS). The triazole derivatives, for example, comprise a central triazole group with two substituents comprising an aryl or heteroaryl group. Exemplary derivatives showed excellent HIV inhibitory activity against both wild-type and selected mutant strains of HIV.

    专利号:WO-2025124470-A1
    优先权日:2023-12-15
    标 题:Doravirine intermediate, and use thereof and synthesis method therefor
    发明人:GAO ZHANGBIN; WEN SHAOPENG; YANG JINHONG; JU JINGJING; MAO WENXIU
    权利人:SHANDONG CHENGCHUANG BLUE SEA PHARMACEUTICAL TECH CO LTD
    摘要:The present invention relates to a doravirine intermediate, and the use thereof and a synthesis method therefor, which belong to the technical field of pharmaceutical chemistry. The method for synthesizing the doravirine intermediate comprises the following steps: (1) mixing ethyl 2-fluoroacetate with 4-ethoxy-1,1,1-trifluoro-3-buten-2-one with solvent I, and then dropwise adding sodium bis(trimethylsilyl)amide to form compound 1; (2) adding an ammonia source into the reaction liquid of compound 1 to obtain compound 2; (3) dissolving compound 2 in solvent II, adding a catalyst, and heating and ring-closing the mixture to obtain compound 3; and (4) dissolving compound 3 in toluene, adding thionyl chloride, and dropwise adding pyridine to obtain 2-hydroxy-3-fluoro-4-trifluoromethylpyridine. The synthesis method of the present invention has a low raw material cost and a short process period, is environmentally friendly, and is suitable for process scaled-up production.

    专利号:US-5935946-A
    优先权日:1997-07-25
    标 题 :Nucleotide analog composition and synthesis method
    发明人:MUNGER JR JOHN D; ROHLOFF JOHN C; SCHULTZE LISA M
    权利人:GILEAD SCIENCES INC
    摘要:The invention provides a composition comprising bis(POC)PMPA and fumaric acid (1:1). The composition is useful as an intermediate for the preparation of antiviral compounds, or is useful for administration to patients for antiviral therapy or prophylaxis. The composition is particularly useful when administered orally. The invention also provides methods to make PMPA and intermediates in PMPA synthesis. Embodiments include lithium t-butoxide, 9-(2-hydroxypropyl) adenine and diethyl p-toluenesulfonylmethoxyphosphonate in an organic solvent such as DMF. The reaction results in diethyl PMPA preparations containing an improved by-product profile compared to diethyl PMPA made by prior methods.

    专利号:CN-118510750-A
    优先权日:2022-01-05
    标 题 :Improved synthesis of rilpivirine glycine particles

    专利号:CN-113388600-B
    优先权日:2021-06-16
    标题:A kind of aldoxime dehydratase and its application in catalytic synthesis of aromatic nitrile compounds
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    宁波申泰生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.syntame.com
    企业联系电话:0574-28802872👤
    📞宁波申泰生物科技有限公司 ⚠️参考联系方式
    联系人:陈女士
    电话:0574-28802872

    传真:0574-28802872
    邮箱:Info@syntame.com
    通信地址: 宁波市鄞州区下应北路789号锐鼎加速器2号楼
    邮编: 315105
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:宁波市鄞州区下应北路789号锐鼎加速器2号楼
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Serris A, Ferre VM, Le Hingrat Q, Bachelard A, Charpentier C, Exarchopoulos M, Damond F, Phung BC, Landman R, Yazdanpanah Y, Descamps D, Joly V, Peytavin G, Ghosn J. Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results. J Antimicrob Chemother. 2024 Sep
    17:dkae308. doi: 10.1093/jac/dkae308. Epub ahead of print. 11(9):ofae480. doi: 10.1093/ofid/ofae480.
    3: Konishi K, Onozuka D, Okubo M, Kasamatsu Y, Kutsuna S, Shirano M. Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting. BMC Infect Dis. 2024 Sep 16;24(1):979. doi: 10.1186/s12879-024-09904-x.

    合成参考文献


    参考文献:10.1016/s0140-6736(11)61106-9
    摘要:HIV/AIDS and the road to Rome. Lancet. 2011 Jul 16;378(9787):199. doi: 10.1016/s0140-6736(11)61106-9.
    参考文献:10.1016/s0140-6736(11)60992-6
    摘要:Schrijvers R, Desimmie BA, Debyser Z. Rilpivirine: a step forward in tailored HIV treatment. Lancet. 2011 Jul 16;378(9787):201–3. doi: 10.1016/s0140-6736(11)60992-6.
    参考文献:10.1016/s0140-6736(11)60983-5
    摘要:Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229–37. doi: 10.1016/s0140-6736(11)60983-5.
    参考文献:10.1016/s0140-6736(11)60936-7
    摘要:Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011 Jul 16;378(9787):238–46. doi: 10.1016/s0140-6736(11)60936-7.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知